Ownership and insider activity for 908 Devices Inc. (MASS): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
908 Devices Inc. provides purpose-built handheld mass spectrometry and fourier transform infrared (FTIR) devices for use in vital health and safety applications. The company’s products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; XplorIR, a handheld device that uses FTIR spectroscopy to identify, quantify, and track gases and vapors; ThreatID, a portable...
Price
| Price | $10.53 |
| Market Cap | $432M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-09-16 | Kenneweg John | M-Exempt | 21,399 | $21K |
| 2026-09-17 | Kenneweg John | M-Exempt | 5,257 | $5K |
| 2026-09-15 | Kenneweg John | M-Exempt | 1,000 | $960 |
| 2026-09-17 | Kenneweg John | S-Sale | 5,257 | $54K |
| 2026-09-15 | Kenneweg John | S-Sale | 1,000 | $10K |
| 2026-09-16 | Kenneweg John | S-Sale | 21,399 | $216K |
| 2026-09-15 | Kenneweg John | M-Exempt | 1,000 | $960 |
| 2026-09-16 | Kenneweg John | M-Exempt | 21,399 | $21K |
| 2026-09-17 | Kenneweg John | M-Exempt | 5,257 | $5K |
| 2026-09-02 | Brown Christopher D. | S-Sale | 30,000 | $317K |
Balance Sheet (10y)
| Year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $7.1M | $17.9M | $159.2M | $224.1M | $188.4M | $121.0M | $44.0M | $113.0M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | $24.6M | $25.6M | 0 |
| Receivables | $6.3M | $5.1M | $6.8M | $16.6M | $10.0M | $9.0M | $12.6M | $11.3M |
| Inventory | $3.5M | $5.2M | $4.6M | $7.9M | $12.5M | $14.9M | $16.2M | $13.0M |
| Total Current Assets | $17.2M | $28.6M | $171.0M | $252.9M | $215.6M | $173.8M | $103.1M | $144.6M |
| Property, Plant & Equipment | $10.0M | $8.6M | $7.1M | $6.8M | $7.0M | $9.6M | $10.3M | $8.6M |
| Goodwill | 0 | 0 | 0 | 0 | $10.1M | $10.4M | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | $8.5M | $7.9M | $45.3M | $36.4M |
| Total Assets | $27.7M | $37.7M | $178.8M | $260.9M | $242.6M | $203.0M | $159.5M | $190.1M |
| Accounts Payable | $645000 | $577000 | $1.0M | $1.4M | $1.4M | $1.2M | $2.1M | $8.4M |
| Short-term Debt | 0 | 0 | $500000 | 0 | 0 | $2.0M | $1.9M | $16.7M |
| Total Current Liabilities | $4.8M | $6.1M | $10.8M | $14.8M | $19.2M | $22.5M | $25.1M | $34.1M |
| Long-term Debt | $9.7M | $14.8M | $14.3M | $15.0M | $15.0M | 0 | 0 | 0 |
| Total Liabilities | $77.9M | $100.8M | $39.8M | $46.3M | $52.0M | $37.5M | $44.9M | $46.4M |
| Retained Earnings | -$52.3M | -$65.6M | -$78.5M | -$100.6M | -$134.2M | -$170.6M | -$242.8M | -$223.3M |
| Total Equity | -$50.2M | -$63.2M | $139.0M | $214.6M | $190.6M | $165.5M | $114.6M | $143.7M |
| Total Debt | $17.9M | $22.8M | $21.9M | $20.9M | $19.5M | $5.9M | $6.6M | $16.7M |
| Net Debt | $10.9M | $4.9M | -$137.4M | -$203.2M | -$168.9M | -$139.7M | -$63.0M | -$96.3M |
| Working Capital | $12.4M | $22.5M | $160.1M | $238.1M | $196.4M | $151.2M | $77.9M | $110.5M |
Financial Health
| Debt / Equity | 0.03 |
| Current Ratio | 2.67 |
Profitability
| Return on Equity | -25.50% |
| Return on Invested Capital | -18.70% |
| Return on Assets | -17.46% |
| Gross Margin | 49.79% |
| Operating Margin | -46.01% |
| Net Margin | -56.68% |
Related companies: ACRS · CAPR · CERS · CVRX · NNOX · NPCE · QTRX
Explore sector: Healthcare · Medical - Specialties
More sections of MASS: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks